Successful Treatment of Klebsiella pneumoniae NDM Sepsis and Intestinal Decolonization with Ceftazidime/Avibactam Plus Aztreonam Combination in a Patient with TTP Complicated by SARS-CoV-2 Nosocomial Infection
Abstract
:1. Introduction
2. Case Report
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Logan, L.K.; Weinstein, R.A. The epidemiology of Carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace. J. Infect. Dis. 2017, 215, S28–S36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nordmann, P.; Dortet, L.; Poirel, L. Carbapenem resistance in Enterobacteriaceae: Here is the storm! Trends Mol. Med. 2012, 18, 263–272. [Google Scholar] [CrossRef]
- Shimasaki, T.; Seekatz, A.; Bassis, C.; Rhee, Y.; Yelin, R.D.; Fogg, L.; Dangana, T.; Cisneros, E.C.; Weinstein, R.A.; Okamoto, K.; et al. Increased Relative Abundance of Klebsiella pneumoniae Carbapenemase-producing Klebsiella pneumoniae within the Gut Microbiota Is Associated with Risk of Bloodstream Infection in Long-term Acute Care Hospital Patients. Clin. Infect. Dis. 2019, 68, 2053–2059. [Google Scholar] [CrossRef] [PubMed]
- Iacchini, S.; Sabbatucci, M.; Gagliotti, C.; Rossolini, G.M.; Moro, M.L.; Iannazzo, S.; D’Ancona, F.; Pezzotti, P.; Pantosti, A. Bloodstream infections due to carbapenemaseproducing Enterobacteriaceae in Italy: Results from nationwide surveillance, 2014 to 2017. Eurosurveillance 2019, 24, 1800159. [Google Scholar] [CrossRef] [PubMed]
- Albiger, B.; Glasner, C.; Struelens, M.J.; Grundmann, H.; Monnet, D.L. Carbapenemase-producing Enterobacteriaceae in Europe: Assessment by national experts from 38 countries, May 2015. Eurosurveillance 2015, 20, 30062. [Google Scholar] [CrossRef] [Green Version]
- Yong, D.; Toleman, M.A.; Giske, C.G.; Cho, H.S.; Sundman, K.; Lee, K.; Walsh, T.R. Characterization of a new metallo-β-lactamase gene, bla NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 2009, 53, 5046–5054. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Falcone, M.; Daikos, G.L.; Tiseo, G.; Bassoulis, D.; Giordano, C.; Galfo, V.; Leonildi, A.; Tagliaferri, E.; Barnini, S.; Sani, S.; et al. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients with Bloodstream Infections Caused by Metallo-β-lactamase–Producing Enterobacterales. Clin. Infect. Dis. 2020. [Google Scholar] [CrossRef]
- Tavoschi, L.; Forni, S.; Porretta, A.; Righi, L.; Pieralli, F.; Menichetti, F.; Falcone, M.; Gemignani, G.; Sani, S.; Vivani, P.; et al. Prolonged outbreak of New Delhi metallo-betalactamase-producing carbapenem-resistant Enterobacterales (NDM-CRE), Tuscany, Italy, 2018 to 2019. Eurosurveillance 2020, 25, 2000085. [Google Scholar] [CrossRef] [Green Version]
- Falcone, M.; Giordano, C.; Barnini, S.; Tiseo, G.; Leonildi, A.; Malacarne, P.; Menichetti, F.; Carattoli, A. Extremely drug-resistant NDM-9-producing ST147 Klebsiella pneumoniae causing infections in Italy, May 2020. Eurosurveillance 2020, 25, 3–8. [Google Scholar]
- Jean, S.-S.; Lee, W.-S.; Lam, C.; Hsu, C.-W.; Chen, R.-J.; Hsueh, P.-R. Carbapenemase-producing Gram-negative bacteria: Current epidemics, antimicrobial susceptibility and treatment options. Future Microbiol. 2015, 10, 407–425. [Google Scholar] [CrossRef]
- Bassetti, M.; Vena, A.; Castaldo, N.; Righi, E.; Peghin, M. New antibiotics for ventilator-associated pneumonia. Curr. Opin. Infect. Dis. 2018, 31, 177–186. [Google Scholar] [CrossRef] [PubMed]
- Mikhail, S.; Singh, N.B.; Kebriaei, R.; Rice, S.A.; Stamper, K.C.; Castanheira, M.; Rybak, M.J. Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2019, 63, e00779-19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marshall, S.; Hujer, A.M.; Rojas, L.J.; Papp-Wallace, K.M.; Humphries, R.M.; Spellberg, B.; Hujer, K.M.; Marshall, E.K.; Rudin, S.D.; Perez, F.; et al. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Antimicrob. Agents Chemother. 2017, 61, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Drawz, S.M.; Papp-Wallace, K.M.; Bonomo, R.A. New β-lactamase inhibitors: A therapeutic renaissance in an MDR world. Antimicrob. Agents Chemother. 2014, 58, 1835–1846. [Google Scholar] [CrossRef] [Green Version]
- Asli, A.; Brouillette, E.; Krause, K.M.; Nichols, W.W.; Malouin, F. Distinctive binding of avibactam to penicillin-binding proteins of gram-negative and gram-positive bacteria. Antimicrob. Agents Chemother. 2016, 60, 752–756. [Google Scholar] [CrossRef] [Green Version]
- Giamarellos-Bourboulis, E.J.; Netea, M.G.; Rovina, N.; Akinosoglou, K.; Antoniadou, A.; Antonakos, N.; Damoraki, G.; Gkavogianni, T.; Adami, M.-E.; Katsaounou, P.; et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe 2020, 27, 992–1000.e3. [Google Scholar] [CrossRef] [PubMed]
- Terpos, E.; Ntanasis-Stathopoulos, I.; Elalamy, I.; Kastritis, E.; Sergentanis, T.N.; Politou, M.; Psaltopoulou, T.; Gerotziafas, G.; Dimopoulos, M.A. Hematological findings and complications of COVID-19. Am. J. Hematol. 2020, 95, 834–847. [Google Scholar] [CrossRef] [Green Version]
- Dobesh, P.P.; Trujillo, T.C. Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. Pharmacotherapy 2020, 40, 1130–1151. [Google Scholar] [CrossRef] [PubMed]
- Cardinale, V.; Capurso, G.; Ianiro, G.; Gasbarrini, A.; Arcidiacono, P.G.; Alvaro, D. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis. Dig. Liver Dis. 2020, 52, 1383–1389. [Google Scholar] [CrossRef]
- Cheung, K.S.; Hung, I.F.; Chan, P.P.; Lung, K.C.; Tso, E.; Liu, R.; Ng, Y.Y.; Chu, M.Y.; Chung, T.W.; Tam, A.R.; et al. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis. Gastroenterology 2020, 159, 81–95. [Google Scholar] [CrossRef]
- Buetti, N.; Ruckly, S.; de Montmollin, E.; Reignier, J.; Terzi, N.; Cohen, Y.; Shiami, S.; Dupuis, C.; Timsit, J.-F. COVID-19 increased the risk of ICU-acquired bloodstream infections: A case–cohort study from the multicentric OUTCOMEREA network. Intensive Care Med. 2021, 47, 180–187. [Google Scholar] [CrossRef] [PubMed]
- Salvarani, C.; Dolci, G.; Massari, M.; Merlo, D.F.; Cavuto, S.; Savoldi, L.; Bruzzi, P.; Boni, F.; Braglia, L.; Turrà, C.; et al. Effect of Tocilizumab vs. Standard Care on Clinical Worsening in Patients Hospitalized with COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern. Med. 2021, 181, 24–31. [Google Scholar] [CrossRef] [PubMed]
- Hermine, O.; Mariette, X.; Tharaux, P.L.; Resche-Rigon, M.; Porcher, R.; Ravaud, P.; Bureau, S.; Dougados, M.; Tibi, A.; Azoulay, E.; et al. Effect of Tocilizumab vs. Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern. Med. 2021, 181, 32–40. [Google Scholar] [CrossRef] [PubMed]
- Aziz, M.; Haghbin, H.; Abu Sitta, E.; Nawras, Y.; Fatima, R.; Sharma, S.; Lee-Smith, W.; Duggan, J.; Kammeyer, J.A.; Hanrahan, J.; et al. Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis. J. Med. Virol. 2021, 93, 1620–1630. [Google Scholar] [CrossRef] [PubMed]
MIC Breakpoint | ||||
---|---|---|---|---|
Antibiotics | MIC | MICS | MICR | |
Cefepime | R | ≥32 | 1 | 4 |
Cefotaxime | R | ≥64 | 1 | 2 |
Ceftazidime | R | ≥64 | 1 | 4 |
Ceftazidime/Avibactam | R | ≥16 | 8 | 8 |
Ceftolozane/Tazobactam | R | ≥32 | 2 | 2 |
Ciprofloxacine | R | ≥4 | 0.25 | 0.5 |
Colistin | S | ≤0.5 | 2 | 2 |
Gentamicine | R | ≥16 | 2 | 4 |
Imipenem | R | ≥16 | 2 | 4 |
Meropenem | R | ≥16 | 2 | 8 |
Piperacilline/Tazobactam | R | ≥128 | 8 | 16 |
Tobramycin | R | ≥−16 | 2 | 2 |
Trimetoprim/Sulfam | R | ≥320 | 40 | 80 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Perrotta, F.; Perrini, M.P. Successful Treatment of Klebsiella pneumoniae NDM Sepsis and Intestinal Decolonization with Ceftazidime/Avibactam Plus Aztreonam Combination in a Patient with TTP Complicated by SARS-CoV-2 Nosocomial Infection. Medicina 2021, 57, 424. https://doi.org/10.3390/medicina57050424
Perrotta F, Perrini MP. Successful Treatment of Klebsiella pneumoniae NDM Sepsis and Intestinal Decolonization with Ceftazidime/Avibactam Plus Aztreonam Combination in a Patient with TTP Complicated by SARS-CoV-2 Nosocomial Infection. Medicina. 2021; 57(5):424. https://doi.org/10.3390/medicina57050424
Chicago/Turabian StylePerrotta, Francesco, and Marco Paolo Perrini. 2021. "Successful Treatment of Klebsiella pneumoniae NDM Sepsis and Intestinal Decolonization with Ceftazidime/Avibactam Plus Aztreonam Combination in a Patient with TTP Complicated by SARS-CoV-2 Nosocomial Infection" Medicina 57, no. 5: 424. https://doi.org/10.3390/medicina57050424